Equillium (NASDAQ:EQ) Rating Increased to Hold at Wall Street Zen

Wall Street Zen upgraded shares of Equillium (NASDAQ:EQ) from a sell rating to a hold rating in a research report report published on Saturday morning.

A number of other research firms also recently weighed in on EQ. Weiss Ratings reiterated a “sell (d-)” rating on shares of Equillium in a report on Monday, December 29th. Zacks Research upgraded Equillium to a “hold” rating in a research note on Thursday, February 26th. Stifel Nicolaus assumed coverage on Equillium in a research note on Wednesday, February 25th. They issued a “buy” rating and a $5.00 price target on the stock. Finally, Roth Mkm assumed coverage on Equillium in a report on Friday. They issued a “buy” rating and a $12.00 price objective for the company. Two equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $6.00.

Equillium Trading Up 19.3%

Shares of NASDAQ EQ opened at $2.47 on Friday. Equillium has a 12 month low of $0.27 and a 12 month high of $2.63. The firm has a market capitalization of $150.41 million, a PE ratio of -3.98 and a beta of 1.81. The firm has a fifty day simple moving average of $1.54 and a two-hundred day simple moving average of $1.42.

Insiders Place Their Bets

In other Equillium news, COO Christine Zedelmayer sold 185,937 shares of Equillium stock in a transaction on Thursday, February 19th. The stock was sold at an average price of $1.76, for a total transaction of $327,249.12. Following the completion of the transaction, the chief operating officer owned 191,444 shares in the company, valued at approximately $336,941.44. The trade was a 49.27% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Over the last three months, insiders sold 485,589 shares of company stock worth $863,704. 31.60% of the stock is owned by company insiders.

Institutional Investors Weigh In On Equillium

Institutional investors have recently modified their holdings of the stock. Virtu Financial LLC increased its holdings in shares of Equillium by 133.4% during the third quarter. Virtu Financial LLC now owns 23,779 shares of the company’s stock valued at $34,000 after acquiring an additional 13,591 shares in the last quarter. State Street Corp boosted its stake in Equillium by 13.0% in the 4th quarter. State Street Corp now owns 155,420 shares of the company’s stock worth $241,000 after purchasing an additional 17,900 shares in the last quarter. Persistent Asset Partners Ltd grew its position in Equillium by 35.0% during the 4th quarter. Persistent Asset Partners Ltd now owns 93,123 shares of the company’s stock valued at $144,000 after purchasing an additional 24,132 shares during the last quarter. Millennium Management LLC purchased a new stake in Equillium during the 3rd quarter valued at about $35,000. Finally, Geode Capital Management LLC increased its stake in Equillium by 11.1% during the 4th quarter. Geode Capital Management LLC now owns 345,310 shares of the company’s stock valued at $535,000 after purchasing an additional 34,491 shares in the last quarter. 27.05% of the stock is owned by hedge funds and other institutional investors.

Key Equillium News

Here are the key news stories impacting Equillium this week:

• Positive Sentiment: RA Capital committed roughly $35 million through a definitive PIPE to advance EQ504 and fund operations into 2029, materially strengthening Equillium’s balance sheet and reducing near-term financing risk. Equillium Announces $35 Million Financing with RA Capital Management
• Positive Sentiment: Roth Capital initiated coverage with a Buy rating and a $12 price target, implying large upside vs. the current trading level — this likely amplified bullish sentiment and buying interest. Roth Capital initiates coverage of Equillium (EQ) with buy recommendation
• Neutral Sentiment: A secondary coverage note: Wall Street Zen moved its rating to Hold, a more muted change that is unlikely to move the stock meaningfully versus the PIPE and Roth initiation. Equillium (NASDAQ:EQ) Rating Increased to Hold at Wall Street Zen
• Neutral Sentiment: Company disclosed the transaction structure: ~18.9M common shares (including pre-funded warrants) priced at $1.854 each; proceeds are earmarked for advancing EQ504 and general corporate purposes. Equillium Raises Capital Through Private Equity Securities Sale
• Negative Sentiment: The financing dilutes existing shareholders (issuance of ~18.9M shares) and RA Capital received registration rights — dilution and potential future share sales could weigh on the stock over time. Equillium Secures $35 Million Funding Commitment from RA Capital to Advance EQ504 Clinical Development
• Negative Sentiment: Recent insider selling has been reported, which may concern some investors about near-term insider confidence. QuiverQuant coverage including insider activity

Equillium Company Profile

Equillium, Inc (NASDAQ: EQ) is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies to treat severe autoimmune diseases and prevent organ transplant rejection. The company’s lead therapeutic candidate, EQ001 (itolizumab), is a humanized monoclonal antibody that modulates T-cell activation by targeting the CD6 receptor. Equillium’s pipeline also includes additional biologic candidates aimed at addressing indications such as acute graft-versus-host disease (GVHD) and lupus nephritis.

Founded in 2015 and headquartered in La Jolla, California, Equillium in-licensed itolizumab from Biocon Limited, leveraging the antibody’s established safety profile in earlier clinical studies.